GLP-1 controls glucose homeostasis by accelerating insulin secretion in a glucose-dependent manner, but it is not prone to a hypoglycemia risk compared with traditional hypoglycemic drugs because of its modulation of glucose-dependent insulin secretion. The gene discussed is INS; the disease is Hypoglycemia.